Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board

Destiny Pharma Plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces the appointment of Professor Mark Wilcox to its Scientific Advisory Board (SAB).

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...